₹372.9
▲ +9.34 +2.57%
16 Jul 2026
NSE Listed
Bajaj HealthCare Limited (BAJAJHCARE)
20-day avg volume: 10.4L shares
- Revenue fell 11% YoY.
- Stock trades at a high P/E of 54.
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹132 Cr | ₹133 Cr | ₹123 Cr | ₹154 Cr | ₹149 Cr | ₹148 Cr | ₹161 Cr | ₹153 Cr |
| EBITDA | ₹19 Cr | ₹20 Cr | ₹17 Cr | ₹18 Cr | ₹20 Cr | ₹22 Cr | ₹25 Cr | ₹18 Cr |
| Net Profit | ₹7 Cr | ₹9 Cr | ₹12 Cr | ₹11 Cr | ₹12 Cr | ₹11 Cr | ₹16 Cr | ₹-23 Cr |
| EPS | — | — | — | — | — | — | — | — |
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹329 Cr | ₹371 Cr | ₹417 Cr | ₹664 Cr | ₹681 Cr | ₹647 Cr | ₹482 Cr | ₹562 Cr |
| EBITDA | ₹30 Cr | ₹32 Cr | ₹43 Cr | ₹127 Cr | ₹102 Cr | ₹96 Cr | ₹57 Cr | ₹74 Cr |
| Net Profit | ₹15 Cr | ₹16 Cr | ₹25 Cr | ₹83 Cr | ₹71 Cr | ₹43 Cr | ₹-84 Cr | ₹39 Cr |
| EPS | 22.01 | 11.82 | 18.29 | 30.11 | 25.87 | 15.59 | -30.36 | 13.12 |
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹283 Cr | ₹343 Cr | ₹526 Cr | ₹721 Cr | ₹898 Cr | ₹765 Cr | ₹833 Cr | ₹923 Cr |
| Total Liabilities | ₹130 Cr | ₹165 Cr | ₹267 Cr | ₹393 Cr | ₹530 Cr | ₹487 Cr | ₹367 Cr | ₹390 Cr |
| Equity | ₹153 Cr | ₹178 Cr | ₹258 Cr | ₹328 Cr | ₹368 Cr | ₹278 Cr | ₹466 Cr | ₹533 Cr |
| Total Debt | — | — | — | — | — | — | — | ₹249 Cr |
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | ₹79 Cr | ₹10 Cr | ₹-11 Cr | ₹105 Cr | ₹26 Cr | ₹58 Cr |
| Investing | ₹-109 Cr | ₹-75 Cr | ₹-93 Cr | ₹-11 Cr | ₹-15 Cr | ₹-48 Cr |
| Financing | ₹75 Cr | ₹62 Cr | ₹131 Cr | ₹-97 Cr | ₹-6 Cr | ₹24 Cr |
| Free Cash Flow | ₹79 Cr | ₹10 Cr | ₹-11 Cr | ₹105 Cr | ₹26 Cr | ₹15 Cr |
Healthcare · Drug Manufacturers - Specialty & Generic
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, phlebotropic drug, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 amino 1 adamantanol, N boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide). In addition, the company offers formulations in the form of tablets, capsules, sachets, and vials, as well as impurities. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.
www.bajajhealth.com ↗As of 2026-03-31
Quarterly — figures in %. Latest 12 quarters.
| Period | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 67.5% | 67.7% | 67.7% | 67.7% | 67.7% | 59.2% | 59.2% | 59.2% | 59.2% | 59.2% | 59.2% | 58.3% |
| FIIs | 0.7% | 0.7% | 0.7% | 0.5% | 0% | 1.1% | 1% | 1% | 1.1% | 1.1% | 1.2% | 2% |
| DIIs | 0.3% | 0.4% | 0% | 0.4% | 0% | 2% | 2.4% | 2.5% | 3.2% | 3% | 3% | 2.9% |
| Public | 31.5% | 31.2% | 31.5% | 31.3% | 32.3% | 37.8% | 37.4% | 37.2% | 36.6% | 36.7% | 36.7% | 36.8% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 27,322 | 28,008 | 29,626 | 32,712 | 32,397 | 31,993 | 32,672 | 35,710 | 35,980 | 38,574 | 37,951 | 38,158 |
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
| Name | Category | Stake | Shares |
|---|---|---|---|
| Sajankumar Rameshwarlal Bajaj | Shareholding of Promoter and Promoter Group | 36.6% | 1.23 Cr |
| Anil Champalal Jain | Shareholding of Promoter and Promoter Group | 5.8% | 19,36,544 |
| Namrata Bajaj | Shareholding of Promoter and Promoter Group | 4.9% | 16,32,207 |
| Nihita Bajaj Kumar | Shareholding of Promoter and Promoter Group | 4.8% | 16,20,360 |
| Babita Sajankumar Bajaj | Shareholding of Promoter and Promoter Group | 4.5% | 15,04,000 |
| Deepak Ramanlal Joshi | Public Shareholding | 2.3% | 7,82,574 |
| Hdfc Mutual Fund - Hdfc Pharma And Healthcare Fund | Public Shareholding | 1.7% | 5,68,918 |
| Vanaja Sundar Iyer | Public Shareholding | 1.6% | 5,33,228 |
| Weststone Management Consultancy Pvt Ltd | Public Shareholding | 1.5% | 5,14,026 |
| Padma Anil Jain | Shareholding of Promoter and Promoter Group | 0.9% | 3,04,000 |
| Bajaj Health And Nutritions Llp | Shareholding of Promoter and Promoter Group | 0.7% | 2,40,000 |
| Bansal Pharma Limited | Shareholding of Promoter and Promoter Group | 0.2% | 60,000 |
| Skr Bajaj Huf | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Padma Anil Jain | 0 | 0% | 2026-03-31 |
| Anil Champalal Jain | 0 | 0% | 2026-03-31 |
| Babita Sajankumar Bajaj | 0 | 0% | 2026-03-31 |
| Nihita Bajaj Kumar | 0 | 0% | 2026-03-31 |
| Namrata Bajaj | 0 | 0% | 2026-03-31 |
| Sajankumar Rameshwarlal Bajaj | 0 | 0% | 2026-03-31 |
| Skr Bajaj Huf | 0 | 0% | 2026-03-31 |
| Bansal Pharma Limited | 0 | 0% | 2026-03-31 |
| Bajaj Health And Nutritions Llp | 0 | 0% | 2026-03-31 |
| Hdfc Mutual Fund - Hdfc Pharma And Healthcare Fund | 0 | 0% | 2026-03-31 |
| Vanaja Sundar Iyer | 0 | 0% | 2026-03-31 |
| Deepak Ramanlal Joshi | 0 | 0% | 2026-03-31 |
| Name | Designation | Year |
|---|---|---|
| Sanjankumar R Bajaj | Chairman / Executive Director / Managing Director | 2025 |
| Namrata S Bajaj | E D & Wholetime Director | 2025 |
| Anil C Jain | Managing Director | 2025 |
| Pakshal Jain | E D & Wholetime Director | 2025 |
| Hemant R Karnik | Independent Non Exe. Director | 2025 |
| Ram B Banarase | Independent Non Exe. Director | 2025 |
| Kejal Shah | Independent Non Exe. Director | 2025 |
| GOPALAKRISHNAN KESAVAN | Independent Non Exe. Director | 2025 |
| Monica Tanwar | Company Sec. & Compli. Officer | 2025 |
| Segment | Revenue | Share |
|---|---|---|
| Bulk Drugs | ₹591 Cr | 86.9% |
| Formulation & Sale of Medicines | ₹89 Cr | 13.1% |
| Others | ₹0 Cr | 0% |
| Region | Revenue | Share |
|---|---|---|
| India | ₹418 Cr | 77.1% |
| Outside India | ₹124 Cr | 22.9% |
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹5 | 25 | 16 | 16 |
| Type | Date | Value | Remark |
|---|---|---|---|
| dividend | 2025-09-19 | ₹1 (20%) | Final |
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 21 | 0 | 22 |
| 2025 | 0 | 0 | 0 | 13 | 0 | 14 |
| 2025 | 0 | 0 | 0 | 8 | 0 | 9 |
21 recent disclosure(s)
13 disclosure(s)
📍 602-606 Bhoomi Velocity Infote, Road No 23 Wagle Indl Estate, Thane, Maharashtra, 400604
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search